簡易檢索 / 詳目顯示

回結果列表
研究生： 王泰元
Wang, Tai-Yuan
論文名稱： 含氟唾液酸-石膽酸混合分子作為增強抑制癌細胞轉移能力的唾液酸轉移酶代謝抑制劑
Fluorinated sialic acid-lithocholic acid hybrid molecules as metabolic inhibitor of sialyltransferase and enhance the ability to inhibit cancer metastasis
指導教授： 李文山
Li, Wen-Shan
林文偉
Lin, Wen-Wei
口試委員： 李文山
Li, Wen-Shan
林文偉
Lin, Wen-Wei
陳焜銘
Chen, Kwun-Min
口試日期： 2021/07/14
學位類別： 碩士
Master
系所名稱： 化學系
Department of Chemistry
論文出版年： 2021
畢業學年度： 109
語文別： 英文
論文頁數： 153
中文關鍵詞： 唾液酸 、唾液酸轉移酶 、石膽酸 、唾液酸轉移酶代謝抑制劑 、癌症轉移
英文關鍵詞： Sialic acid, Sialyltransferase, Lithocholic acid, Sialyltransferase metabolic inhibitor, Cancer metastasis
研究方法: 實驗設計法 、 行動研究法 、 準實驗設計法
DOI URL： http://doi.org/10.6345/NTNU202100933
論文種類： 學術論文
相關次數： 點閱：117  下載：0 
分享至:
查詢本校圖書館目錄 查詢臺灣博碩士論文知識加值系統 勘誤回報

    • 含氟唾液酸可以抑制唾液酸轉移酶的活性，以調節唾液酸的生物合成及其補救途徑，加上石膽酸本身也表現出對唾液酸轉移酶的顯著抑制特性。在本篇論文中，我們合成了一系列具有糖苷酯鍵和酯鍵連接的含氟唾液酸-石膽酸混合分子。希望它們可以與唾液酸轉移酶相互作用並協同調控唾液酸的生物合成，以抑制細胞表面唾液酸化的發生。
    最後，我們合成了一系列混合分子TYW01-TYW12，並進行了初步的生物試驗。令人驚訝的是，TYW01-TYW12對唾液酸轉移酶沒有抑制作用，但對人類三陰性乳癌細胞株MDA-MB-231有輕微的抗轉移作用。其中，TYW10的影響較為顯著，IC50範圍為40 µM至50 µM。需要更進一步的生物實驗和研究來證實這些結果。

    Sialyltransferases (STs) activity can be inhibited using a fluorinated sialic acid (3FaxNeu5Ac) to affect/regulate both the de novo synthesis of sialic acid and its salvage pathway. In addition, lithocholic acid (LCA) itself also demonstrated potent inhibitory property toward STs. In this work, we synthesized a series of P-3FaxNeu5Ac-GA-LCA (GA, Glycolic acid) hybrid molecules with glycosidic ester bonds linkage. Hopefully, they can interact with STs and manipulate the biosynthesis of sialic acid synergistically to inhibit/modulate the occurrence of sialylation on cell surface.
    Finally, we synthesized a series of hybrid molecules TYW01-TYW12 and tested their preliminary biological experiments. Surprisingly, TYW01-TYW12 showed no inhibitory effect toward sialyltransferase, but mild anti-migration effect in MDA-MB-231 cell. Among them, TYW10 has the best effect with IC50 ranging from 40 µM to 50 µM. Further biological experiments and studies are needed to confirm these results.

    I. Introduction 1 1.1 Background 1 1.2 Sialic acid 2 1.3 Sialyltransferase 4 1.4 Sialyltransferase inhibitors 6 1.4.1 Inhibitor of donor analogs 6 1.4.2 Inhibitor of transistion-state analogs 7 1.4.3 Inhibitor of acceptor analogs 7 1.4.4 Other sialyltransferase inhibitors 8 1.5 Metabolic inhibition of sialyltransferase 9 1.5.1 The mechanism of metabolic inhibition 10 1.5.2 Fluorinated sialic acid analogs act as metabolic sialyltransferase inhibitors 11 1.6 Previous work 14 1.7 Research motivation 17 II. Results and Discussion 18 2.1 Synthesis strategy 18 2.1.1 Retrosynthetic Analysis 20 2.1.2 Synthesis of glycosyl donors 21 2.1.2 Synthesis of glycosyl acceptors 23 2.1.3 Synthesis of PEG linker 24 2.1.4 Synthesis of sialic acid-lithocholic acid hybrid molecules 25 2.1.5 Synthesis of fluorinated sialic acid-lithocholic acid hybrid molecules 26 2.1.6 Synthesis of modified fluorinated sialic acid-lithocholic acid hybrid molecules and fluorinated sialic acid analogues 27 2.2 Biological experiments in vitro studies 29 2.2.1 Cytotoxicity of TYW01-TYW12 in MDA-MB-231 cell 29 2.2.2 Bioactivity on ST3Gal I and ST6Gal I 31 2.2.3 Anti-migration effect of TYW01-TYW12 33 III. Conclusion 35 IV. Material and Methods 36 4.1 General experimental procedure 36 4.2 Synthetic methods 37 4.2.1 Preparation of glycosyl donors 37 4.2.2 Peparation of glycosyl acceptors 42 4.2.3 Peparation of PEG linker 47 4.2.4 Peparation of P-3FaxNeu5Ac 48 4.2.5 Peparation of TYW01 and TYW02 49 4.2.6 Peparation of TYW03 and TYW04 51 4.2.7 Peparation of TYW05 and TYW06 54 4.2.8 Peparation of TYW07 and TYW08 56 4.2.9 Peparation of TYW09 59 4.2.10 Peparation of TYW10 60 4.2.11 Peparation of TYW11 and TYW12 62 4.3 Bioassay methods 64 4.3.1 Cell line used in bioassay 64 4.3.2 MTT cytotoxicity assay 64 4.3.3 Sialyltransferase activity assay 64 4.3.4 Transwell migration assay 65 References 66 Appendix-Spectra 72

    1. Steeg, P. S., Targeting metastasis. Nat. Rev. Cancer 2016, 16, 201-218.
    2. Fidler, I. J., The pathogenesis of cancer metastasis: the'seed and soil'hypothesis revisited. Nat. Rev. Cancer 2003, 3, 453-458.
    3. Gómez-Cuadrado, L.; Tracey, N.; Ma, R.; Qian, B.; Brunton, V. G., Mouse models of metastasis: progress and prospects. Dis. Model. Mech. 2017, 10, 1061-1074.
    4. Büll, C.; Stoel, M. A.; den Brok, M. H.; Adema, G. J., Sialic acids sweeten a tumor's life. Cancer Res. 2014, 74, 3199-3204.
    5. Rodrigues, J. G.; Balmaña, M.; Macedo, J. A.; Poças, J.; Fernandes, Â.; de-Freitas-Junior, J. C. M.; Pinho, S. S.; Gomes, J.; Magalhães, A.; Gomes, C., Glycosylation in cancer: Selected roles in tumour progression, immune modulation and metastasis. Cell. Immunol. 2018, 333, 46-57.
    6. Rodrigues, E.; Macauley, M. S., Hypersialylation in cancer: modulation of inflammation and therapeutic opportunities. Cancers 2018, 10, 207.
    7. Wang, B.; Brand-Miller, J., The role and potential of sialic acid in human nutrition. Eur. J. Clin. Nutr. 2003, 57, 1351-1369.
    8. Moons, S. J.; Adema, G. J.; Derks, M. T.; Boltje, T. J.; Büll, C., Sialic acid glycoengineering using N-acetylmannosamine and sialic acid analogs. Glycobiology 2019, 29, 433-445.
    9. Varki, A.; Cummings, R. D.; Esko, J. D.; Stanley, P.; Hart, G. W.; Aebi, M.; Darvill, A. G.; Kinoshita, T.; Packer, N. H.; Prestegard, J. H., Essentials of Glycobiology [internet]. 2015.
    10. Stencel-Baerenwald, J. E.; Reiss, K.; Reiter, D. M.; Stehle, T.; Dermody, T. S., The sweet spot: defining virus–sialic acid interactions. Nat. Rev. Microbiol. 2014, 12, 739-749.
    11. Taniguchi, N.; Endo, T.; Hart, G. W.; Seeberger, P. H.; Wong, C.-H., Glycoscience: Biology and Medicine. Springer: 2015.
    12. Zhou, X.; Yang, G.; Guan, F., Biological functions and analytical strategies of sialic acids in tumor. Cells 2020, 9, 273.
    13. Jacobs, C. L.; Goon, S.; Yarema, K. J.; Hinderlich, S.; Hang, H. C.; Chai, D. H.; Bertozzi, C. R., Substrate specificity of the sialic acid biosynthetic pathway. Biochemistry 2001, 40, 12864-12874.
    14. Montgomery, A.; Szabo, R.; Skropeta, D.; Yu, H., Computational characterisation of the interactions between human ST6Gal I and transition‐state analogue inhibitors: insights for inhibitor design. J. Mol. Recognit. 2016, 29, 210-222.
    15. Szabo, R.; Skropeta, D., Advancement of sialyltransferase inhibitors: therapeutic challenges and opportunities. Med. Res. rev. 2017, 37, 219-270.
    16. Harduin-Lepers, A.; Vallejo-Ruiz, V.; Krzewinski-Recchi, M.-A.; Samyn-Petit, B.; Julien, S.; Delannoy, P., The human sialyltransferase family. Biochimie 2001, 83, 727-737.
    17. Wang, L.; Liu, Y.; Wu, L.; Sun, X.-L., Sialyltransferase inhibition and recent advances. Biochim Biophys Acta Proteins Proteom 2016, 1864, 143-153.
    18. Whalen, L. J.; McEvoy, K. A.; Halcomb, R. L., Synthesis and evaluation of phosphoramidate amino acid-based inhibitors of sialyltransferases. Bioorg. Med. Chem. Lett. 2003, 13, 301-304.
    19. Rillahan, C. D.; Antonopoulos, A.; Lefort, C. T.; Sonon, R.; Azadi, P.; Ley, K.; Dell, A.; Haslam, S. M.; Paulson, J. C., Global metabolic inhibitors of sialyl-and fucosyltransferases remodel the glycome. Nat. Chem. Biol. 2012, 8, 661-668.
    20. Natoni, A.; Farrell, M. L.; Harris, S.; Falank, C.; Kirkham-McCarthy, L.; Macauley, M. S.; Reagan, M. R.; O’Dwyer, M., Sialyltransferase inhibition leads to inhibition of tumor cell interactions with E-selectin, VCAM1, and MADCAM1, and improves survival in a human multiple myeloma mouse model. Haematologica 2020, 105, 457.
    21. Büll, C.; Boltje, T. J.; Wassink, M.; de Graaf, A. M.; van Delft, F. L.; den Brok, M. H.; Adema, G. J., Targeting aberrant sialylation in cancer cells using a fluorinated sialic acid analog impairs adhesion, migration, and in vivo tumor growth. Mol. Cancer Ther. 2013, 12, 1935-1946.
    22. Müller, B.; Schaub, C.; Schmidt, R. R., Efficient sialyltransferase inhibitors based on transition‐state analogues of the sialyl donor. Angew. Chem. Int. Ed. 1998, 37, 2893-2897.
    23. Schwörer, R.; Schmidt, R. R., Efficient sialyltransferase inhibitors based on glycosides of N-acetylglucosamine. J. Am. Chem. Soc. 2002, 124, 1632-1637.
    24. Li, W.; Niu, Y.; Xiong, D.-C.; Cao, X.; Ye, X.-S., Highly substituted cyclopentane–CMP conjugates as potent sialyltransferase inhibitors. J. Med. Chem. 2015, 58, 7972-7990.
    25. Guo, J.; Li, W.; Xue, W.; Ye, X.-S., Transition state-based sialyltransferase inhibitors: mimicking oxocarbenium ion by simple amide. J. Med. Chem. 2017, 60, 2135-2141.
    26. Montgomery, A. P.; Dobie, C.; Szabo, R.; Hallam, L.; Ranson, M.; Yu, H.; Skropeta, D., Design, synthesis and evaluation of carbamate-linked uridyl-based inhibitors of human ST6Gal I. Bioorg. Med. Chem. 2020, 28, 115561.
    27. Kajihara, Y.; Kodama, H.; Wakabayashi, T.; Sato, K.-i.; Hashimoto, H., Characterization of inhibitory activities and binding mode of synthetic 6′-modified methyl N-acetyl-β-lactosaminide toward rat liver CMP-D-Neu5Ac: d-galactoside-(2→ 6)-α-d-sialyltransferase. Carbohydr. Res. 1993, 247, 179-193.
    28. Wu, C.-Y.; Hsu, C.-C.; Chen, S.-T.; Tsai, Y.-C., Soyasaponin I, a potent and specific sialyltransferase inhibitor. Biochem. Biophys. Res. Commun. 2001, 284, 466-469.
    29. Lin, T.-W.; Chang, W.-W.; Chen, C.-C.; Tsai, Y.-C., Stachybotrydial, a potent inhibitor of fucosyltransferase and sialyltransferase. Biochem. Biophys. Res. Commun. 2005, 331, 953-957.
    30. Chang, K.-H.; Lee, L.; Chen, J.; Li, W.-S., Lithocholic acid analogues, new and potent α-2, 3-sialyltransferase inhibitors. Chem. Commun. 2006, 629-631.
    31. Gloster, T. M.; Zandberg, W. F.; Heinonen, J. E.; Shen, D. L.; Deng, L.; Vocadlo, D. J., Hijacking a biosynthetic pathway yields a glycosyltransferase inhibitor within cells. Nat. Chem. Biol. 2011, 7, 174-181.
    32. Burkart, M. D.; Vincent, S. P.; Düffels, A.; Murray, B. W.; Ley, S. V.; Wong, C.-H., Chemo-enzymatic synthesis of fluorinated sugar nucleotide: useful mechanistic probes for glycosyltransferases. Bioorg. Med. Chem. 2000, 8, 1937-1946.
    33. Heise, T.; Pijnenborg, J. F.; Büll, C.; van Hilten, N.; Kers-Rebel, E. D.; Balneger, N.; Elferink, H.; Adema, G. J.; Boltje, T. J., Potent metabolic sialylation inhibitors based on C-5-modified fluorinated sialic acids. J. Med. Chem. 2018, 62, 1014-1021.
    34. Lairson, L.; Henrissat, B.; Davies, G.; Withers, S., Glycosyltransferases: structures, functions, and mechanisms. Annu. Rev. Biochem. 2008, 77, 521-555.
    35. Macauley, M. S.; Arlian, B. M.; Rillahan, C. D.; Pang, P.-C.; Bortell, N.; Marcondes, M. C. G.; Haslam, S. M.; Dell, A.; Paulson, J. C., Systemic blockade of sialylation in mice with a global inhibitor of sialyltransferases. J. Biol. Chem. 2014, 289, 35149-35158.
    36. Büll, C.; Boltje, T. J.; van Dinther, E. A.; Peters, T.; de Graaf, A. M.; Leusen, J. H.; Kreutz, M.; Figdor, C. G.; den Brok, M. H.; Adema, G. J., Targeted delivery of a sialic acid-blocking glycomimetic to cancer cells inhibits metastatic spread. ACS Nano 2015, 9, 733-745.
    37. Chen, J.-Y.; Tang, Y.-A.; Huang, S.-M.; Juan, H.-F.; Wu, L.-W.; Sun, Y.-C.; Wang, S.-C.; Wu, K.-W.; Balraj, G.; Chang, T.-T., A novel sialyltransferase inhibitor suppresses FAK/paxillin signaling and cancer angiogenesis and metastasis pathways. Cancer Res. 2011, 71, 473-483.
    38. Fu, C.-W.; Tsai, H.-E.; Chen, W.-S.; Chang, T.-T.; Chen, C.-L.; Hsiao, P.-W.; Li, W.-S., Sialyltransferase Inhibitors Suppress Breast Cancer Metastasis. J. Med. Chem. 2020, 64, 527-542.
    39. Nishino, R.; Ikeda, K.; Hayakawa, T.; Takahashi, T.; Suzuki, T.; Sato, M., Syntheses of 2-deoxy-2, 3-didehydro-N-acetylneuraminic acid analogues modified by N-sulfonylamidino groups at the C-4 position and biological evaluation as inhibitors of human parainfluenza virus type 1. Bioorg. Med. Chem. 2011, 19, 2418-2427.
    40. Xiong, D.-C.; Zhou, Y.; Cui, Y.; Ye, X.-S., Synthesis of triazolyl-linked polysialic acids. Tetrahedron 2014, 70, 9405-9412.
    41. Bolitt, V.; Mioskowski, C.; Lee, S.; Falck, J., Direct preparation of 2-deoxy-D-glucopyranosides from glucals without Ferrier rearrangement. J. Org. Chem. 1990, 55, 5812-5813.
    42. Burkart, M. D.; Vincent, S. P.; Wong, C.-H., An efficient synthesis of CMP-3-fluoroneuraminic acid. Chem. Commun. 1999, 1525-1526.
    43. Burkart, M. D.; Zhang, Z.; Hung, S.-C.; Wong, C.-H., A new method for the synthesis of fluoro-carbohydrates and glycosides using selectfluor. J. Am. Chem. Soc. 1997, 119, 11743-11746.
    44. Hayashi, T.; Kehr, G.; Bergander, K.; Gilmour, R., Stereospecific α‐Sialylation by Site‐Selective Fluorination. Angew. Chem. Int. Ed. 2019, 58, 3814-3818.
    45. Cai, S.; Yu, B., Efficient sialylation with phenyltrifluoroacetimidates as leaving groups. Org. Lett. 2003, 5, 3827-3830.
    46. Seroka, B.; Łotowski, Z.; Hryniewicka, A.; Rárová, L.; R Sicinski, R.; M Tomkiel, A.; W Morzycki, J., Synthesis of New Cisplatin Derivatives from Bile Acids. Molecules 2020, 25, 655.
    47. Masuno, H.; Kazui, Y.; Tanatani, A.; Fujii, S.; Kawachi, E.; Ikura, T.; Ito, N.; Yamamoto, K.; Kagechika, H., Development of novel lithocholic acid derivatives as vitamin D receptor agonists. Bioorg. Med. Chem. 2019, 27, 3674-3681.
    48. Hashimoto, M.; Liu, Y.; Fang, K.; Li, H.-y.; Campiani, G.; Nakanishi, K., Preparation and biological properties of biotinylated PhTX derivatives. Bioorg. Med. Chem. 1999, 7, 1181-1194.

    下載圖示
    QR CODE